Latest Rheumatology Stories
Massage Envy and the Arthritis Foundation partner together to raise awareness and funds to fight arthritis. Ontario, CA (PRWEB) September 30, 2012 Massage Envy Spas, the nationwide massage and spa services company, hosted a one-day, in-clinic nationwide event called Healing Hands for Arthritis on September 19, 2012. The special promotion provided $10 from every one-hour massage and facial session as a donation to the Arthritis Foundation. The Healing Hands for Arthritis special event is...
After a new study on osteoarthritis has brought a great deal of attention to possible osteoarthritis treatments, the anti-aging company, http://antiagingproductsreviewed.com/ has announced a new report on the Marine D3 supplement and how it may help with osteoarthritis issues. Houston, TX. (PRWEB) September 30, 2012 A new wildly publicized study on osteoarthritis patients has been published and shown to provide new hope from those who suffer from this condition. This study has also...
Lee Rannals for redOrbit.com - Your Universe Online Eating cherries may lower your risk of a certain type of inflammatory arthritis attack, according to a study published in Arthritis & Rheumatism. Researchers found that patients with gout who consumed cherries over a two-day period showed a 35 percent lower risk of having attacks compared to those who did not eat the fruit. The scientists recruited 633 gout patients for the study, and followed them for a one year period....
Support for People in Nebraska, Iowa and Eastern South Dakota DANVERS, Mass., Sept. 28, 2012 /PRNewswire-USNewswire/ -- The Scleroderma Foundation announced today that it has chartered a new chapter to help people living with scleroderma in the states of Iowa, Nebraska and eastern South Dakota. This means more support for individuals with the debilitating autoimmune illness in the central United States. The Scleroderma Foundation, Heartland Chapter is the Foundation's 24th chapter....
BRIDGEWATER, N.J., Sept. 20, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that several abstracts related to KRYSTEXXA(®) (pegloticase) in the treatment of patients with Refractory Chronic Gout (RCG) will be presented at the 2012 ACR/ARHP Annual Meeting taking place in Washington D.C., from November 9-14, 2012. Full text of the following accepted abstracts can be accessed by visiting the American College of Rheumatology website at...
ANAHEIM, Calif., Sept. 19, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will conduct a conference call to discuss the reimbursement process for H.P. Acthar Gel (repository corticotrophin injection) prescriptions. The call will take place on Thursday, September 20, 2012 at 11 a.m. ET, 8 a.m. PT. The call can be accessed in the following ways: By webcast: At Questcor's investor relations website: http://ir.questcor.com/. By telephone:...
TORONTO, Sept. 19, 2012 /PRNewswire/ -- There's no doubt as to the revolutionary nature of the Myoguide(TM) Needle EMG Guided Injection System. This breakthrough technology, developed by Canada's Intronix Technologies (http://www.intronixtech.com), is now giving practitioners a powerfully superior, much safer way to deliver targeted injections of Botox®, and other medication, for myofascial pain, spasticity, fibromyalgia and even cosmetics. Yet the benefits of the Myoguide(TM)...
A pain expert examines John F. Kennedy’s medical history and highlights how a genetic autoimmune disorder JFK suffered became centralized intractable pain. Crucial article for pain practitioners who want to understand why autoimmune disorders are important in treating pain. Montclair, NJ (PRWEB) September 18, 2012 What can patients and physicians learn from JFK’s pain story today? It is now believed that JFK suffered from an autoimmune disease that emerged in early childhood and...
HORSHAM, Pa., Sept. 18, 2012 /PRNewswire/ -- Janssen Biotech, Inc. announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of an investigational intravenous formulation of the anti-tumor necrosis factor (TNF)-alpha SIMPONI(®) (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). An estimated 1.5 million Americans are living with RA,[1] a chronic...
Arthritis Alliance of Canada Launches Framework for Improved Policies and Practices CALGARY, Sept. 18, 2012 /CNW/ - A nationwide coalition of more than thirty groups including patients, health care providers, researchers, care organizations and industry partners today called upon Canadians to designate improved arthritis prevention and care as an urgent national priority. The Arthritis Alliance of Canada (AAC) outlined a plan to address this critical issue facing the country...
